4.6 Article

Tear Dysfunction and the Cornea: LXVIII Edward Jackson Memorial Lecture

期刊

AMERICAN JOURNAL OF OPHTHALMOLOGY
卷 152, 期 6, 页码 900-909

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2011.08.023

关键词

-

资金

  1. Allergan
  2. Alcon
  3. GlaxoSmithKline
  4. National Institute of Health (Bethesda, Maryland) [EY11915, RO1EY018090]
  5. Research to Prevent Blindness (New York, New York)
  6. Oshman Foundation (Houston, Texas)
  7. William Stamps Farish Fund (Houston, Texas)
  8. Hamill Foundation (Houston, Texas)
  9. Allergan, Inc (Irvine, California)

向作者/读者索取更多资源

PURPOSE: To describe the cause and consequence of tear dysfunction-related corneal disease. DESIGN: Perspective on effects of tear dysfunction on the cornea. METHODS: Evidence is presented on the effects of tear dysfunction on corneal morphology, function, and health, as well as efficacy of therapies for tear dysfunction-related corneal disease. RESULTS: Tear dysfunction is a prevalent eye disease and the most frequent cause for superficial corneal epithelial disease that results in corneal barrier disruption, an irregular optical surface, light scattering, optical aberrations, and exposure and sensitization of pain-sensing nerve endings (nociceptors). Tear dysfunction-related corneal disease causes irritation and visual symptoms such as photophobia and blurred and fluctuating vision that may decrease quality of life. Dysfunction of 1 or more components of the lacrimal functional unit results in changes in tear composition, including elevated osmolarity and increased concentrations of matrix metalloproteinases, inflammatory cytokines, and chemokines. These tear compositional changes promote disruption of tight junctions, alter differentiation, and accelerate death of corneal epithelial cells. CONCLUSIONS: Corneal epithelial disease resulting from tear dysfunction causes eye irritation and decreases visual function. Clinical and basic research has improved understanding of the pathogenesis of tear dysfunction-related corneal epithelial disease, as well as treatment outcomes. (Am J Ophthalmol 2011;152:900-909. (C) 2011 by Elsevier Inc. All rights reserved.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据